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RESEARCH LETTER
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ates of infective endocarditis (IE), an infection
that can result from injection-drug use (IDU),
have risen alongside the opioid epidemic.1-3
While previous studies have characterized
hospitalizations for injection drug use-related IE,3,4
comparing hospitalization characteristics between
people who inject drugs (PWID) and non-PWID may
explain different outcomes between IE patients. It
could also be used to inform the development of
cost-effective optimal care models, which may
differ between PWID5,6 and non-PWID. Here, we
compare inpatient hospitalization characteristics,
including care charges, between PWID and nonPWID with IE at a large academic medical center.

METHODS
We performed a cross-sectional analysis of adult
patients (≥ 18 years old) diagnosed with IE and
admitted to a Maine Medical Center (Portland, ME)
between January 1, 2013 and January 1, 2016. IE
was defined by Duke’s criteria as definite or possible
endocarditis on transesophageal echocardiograms.
Patients were classified as PWID if IDU or clinical
suspicion of IDU was documented in the electronic
medical record (EMR). Only the first admission for
IE during the study period was included.
For each admission, we retrospectively obtained
data from the hospital’s billing department, including
total hospital charges (e.g., surgery, anesthesia,
stay in the intensive care unit, antibiotics), amount
paid by insurance, and outstanding hospital
charges. For insured patients, insurance paid 100%
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of total charges. We obtained EMR data on patient
demographics, insurance status, length of stay
(LOS), in-hospital mortality, and cardiac surgery
during the hospitalization.
We summarized variables as mean [standard
deviation (SD)], median (range), or frequency.
We compared characteristics between PWID and
non-PWID using Mann-Whitney U tests, Student’s
t-tests, chi-square tests, or Fisher’s exact tests.
We used SPSS, version 25 (Armonk, NY) for all
analyses. The Maine Medical Center Institutional
Review Board approved this study.

RESULTS
We identified 42 cases of IE among PWID (39%) and
65 among non-PWID (61%). PWID were younger
(mean [SD]: 34.8 [9.1] vs. 63.1 [15.7] years; P <
.001), less likely to have a primary care provider
(71.4% vs. 89.2%, P = .04), and had a different
insurance payer distribution (P < .001) than nonPWID (Table 1). PWID had a longer LOS (median:
18.4 vs 11.9 days) and were more likely to complete
their intravenous antibiotics in the hospital (35.7%
vs. 4.6%) compared to non-PWID.
Median total hospital charges were $149,131
(range: $16,282-$630,151) for PWID and $80,903
(range: $16,902-$736,328) for non-PWID (P = .08;
Figure 1). Among patients with IE, total charges per
day paid by insurance did not vary between PWID
[median: $6,924 (range: $3,778-25,803)] and nonPWID [median: $7,212 (range: $259-97,147)] (P
= .99). Among insured IE patients, total hospital
charges paid by insurance were significantly higher
for PWID [median: $174,573 (range: $16,282$630,151)] than non-PWID [median: $80,903
1
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(range: $16,902-$736,328)] (P = .03). Of the 11
uninsured PWID, five received a hospital write-off
of their bill, totaling $414,886 (median: $53,621 per
patient). Six uninsured PWID and two uninsured
non-PWID had non-covered hospital charges
(median: $105,401 and $83,678 per patient,
respectively).

DISCUSSION

Among patients hospitalized for IE, median total
hospital charges and charges paid by insurance
were approximately twice as high for PWID as
non-PWID. Higher charges among PWID resulted
from their longer LOS, which may be due to more
frequent completion of antibiotic treatment before
hospital discharge. At our institution and others, a
common practice is to not discharge PWID with a
peripherally inserted central catheter (PICC) line
due to concerns related to risk of line misuse and
subsequent infection.7,8 Similarities in daily hospital

charges and cardiac surgery requirements between
PWID and non-PWID suggest that intensity of
care did not differ by IDU. Outpatient antibiotic
management, which was not included, represents
an additional cost.
Over a three-year period at a single hospital,
median charges for IE hospitalization among PWID
exceeded those for non-PWID by $63,228. Despite
our study’s limitations (i.e., potential misclassification
of PWID and inclusion of a single hospital), these
data suggest that IDU-associated IE creates an
additional financial burden to hospitals, payers,
and the patient. Future research should investigate
optimal models of care (e.g., medical respite, patientdirected discharges) for administering antibiotics
to PWID with infections. Finally, improving access
to medication for addiction treatment and harm
reduction strategies may prevent serious bacterial
complications associated with IDU.

Figure 1. Box plots for hospital charges associated with infective endocarditis
among people who inject drugs (PWID) and non-PWID.
Box =25th and 75th percentiles; bars = min and max values.
*Among patients with insurance (n=31 PWID; n=63 non-PWID)
†Mann-Whitney U test, p=0.08
‡Mann-Whitney U test, p=0.03
Abbreviations: PWID, people who inject drugs
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Table 1. Characteristics of 107
infective
patients,charges
by injection drug use.
Ramirez
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N (%)
Age (years), mean (SD)
Male
Race
Caucasian
Black
Unknown
Had primary care provider
Length of stay (days), median (range)
Cardiac surgery during admission
Discharged with IV antibiotics via PICC
Discharge Disposition†
Home with PICC
Care Facility with PICC
Deceased/CMO
Left early (i.e. against medical advice)
wwithout PICC
Completed antibiotics in hospital

Injection drug use, N (%)
Yes
No
42 (39.3)
65 (60.7)
34.8 (9.1)
63.1 (15.7)
27 (64.3)
47 (72.3)

<0.001*
0.51

41 (97.6)
0 (0.0)
1 (2.4)
30 (71.4)
18.4 (2.2-86.7)
14 (33.3)
17 (40.5)

0.04
0.02
0.56
<0.001

62 (95.4)
1 (1.5)
2 (3.1)
58 (89.2)
11.9 (0.2-101.4)
17 (26.2)
51 (78.4)

p-value

<0.001
12 (28.6)
3 (7.1)
4 (9.5)
5 (11.9)

30 (46.2)
16 (24.6)
10 (15.4)
0 (0.0)

15 (35.7)

3 (4.6)

Unknown
3 (7.1)
6 (9.2)
Insurance payer
<0.001
Private only
1 (2.4)
18 (27.7)
Medicaid only
25 (59.5)
13 (20.0)
Medicare only
4 (9.5)
19 (29.2)
>1 Insurance
1 (2.4)
13 (20.0)
Uninsured
11 (26.2)
2 (3.1)
Abbreviations: CMO, comfort measures only; PICC, peripherally inserted central catheter
*p-values calculated using t-test, Fisher’s exact test, Mann-Whitney U test, and Chi square test with
continuity correction as appropriate.
†Percentages do not sum to 100% due to rounding.
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